Titre:
  • Telaprevir for retreatment of HCV infection.
Auteur:Zeuzem, Stefan; Andreone, Pietro; Pol, Stanislas; Lawitz, Eric; Diago, Moises; Roberts, Stuart; Focaccia, Roberto; Younossi, Zobair; Foster, Graham R; Horban, Andrzej; Ferenci, Peter; Nevens, Frederik; Müllhaupt, Beat; Pockros, Paul; Terg, Ruben; Shouval, Daniel; van Hoek, Bart; Weiland, Ola; Van Heeswijk, Rolf; De Meyer, Sandra; Luo, D; Boogaerts, Griet; Polo, Ramon; Picchio, Gaston; Beumont, Maria; Moreno, Christophe
Informations sur la publication:The New England journal of medicine, 364, 25, page (2417-2428)
Statut de publication:Publié, 2011-06
Sujet CREF:Sciences bio-médicales et agricoles
MeSH keywords:Adult
Aged
Antiviral Agents -- adverse effects -- therapeutic use
Double-Blind Method
Drug Therapy, Combination
Female
Genotype
Hepacivirus -- genetics -- isolation & purification
Hepatitis C, Chronic -- drug therapy -- virology
Humans
Interferon-alpha -- adverse effects -- therapeutic use
Logistic Models
Male
Middle Aged
Oligopeptides -- adverse effects -- therapeutic use
Polyethylene Glycols -- adverse effects -- therapeutic use
RNA, Viral -- blood
Recombinant Proteins
Recurrence
Retreatment
Ribavirin -- adverse effects -- therapeutic use
Sequence Analysis, DNA
Serine Proteinase Inhibitors -- adverse effects -- therapeutic use
Viral Load
Young Adult
Note générale:Clinical Trial, Phase III
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langue:Anglais
Identificateurs:urn:issn:0028-4793
info:doi/10.1056/NEJMoa1013086
info:pmid/21696308